Request Demo

Last update 05 Aug 2026

Aficamten

Last update 05 Aug 2026

Overview

R&D Status

Clinical Result

Translational Medicine

Overview

Basic Info

Drug Type

Small molecule drug

Synonyms

艾非凯泰, BAY-3723113, CK 274

+ [5]

Target

Cardiac myosin

Action

inhibitors

Mechanism

Cardiac myosin inhibitors

Therapeutic Areas

Cardiovascular Diseases

Active Indication

Hypertrophic obstructive cardiomyopathyHypertrophic Cardiomyopathy without ObstructionCardiomyopathy, Hypertrophic

Inactive Indication-

Originator Organization

Cytokinetics, Inc.

Active Organization

Cytokinetics, Inc.

Bayer AG

Inactive Organization

Thermo Fisher Scientific, Inc.

License Organization

Royalty Pharma Plc

Corxel Pharmaceuticals (Shanghai) Co., Ltd

Sanofi

+ [2]

Drug Highest PhaseApproved

First Approval Date

China (16 Dec 2025),

Hypertrophic obstructive cardiomyopathy

RegulationBreakthrough Therapy (United States), Orphan Drug (United States), Orphan Drug (Japan), Orphan Drug (Switzerland), Breakthrough Therapy (China), Priority Review (China)

Structure/Sequence

Molecular FormulaC18H19N5O2

InChIKeyIOVAZWDIRCRMTM-OAHLLOKOSA-N

CAS Registry2364554-48-1

Clinical Trials associated with Aficamten

NCT07600177

/ RecruitingPhase 4IIT

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

This is an investigator-initiated two-center study. The goal of this study is to investigate the feasibility, safety and efficacy outcomes of a seamless transition from mavacamten to aficamten in patients with obstructive hypertrophic cardiomyopathy (oHCM).

Start Date05 May 2026

Sponsor / Collaborator

Oregon Health & Science University

[+1]

NCT07023341

/ Active, not recruitingPhase 3

A Phase 3, Open Label, Single Arm Study to Evaluate Efficacy, Safety and Tolerability of Aficamten in Adult Japanese Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy

Researchers are looking for a better way to treat Japanese people who have symptomatic obstructive hypertrophic cardiomyopathy (symptomatic oHCM).
Obstructive hypertrophic cardiomyopathy (oHCM) is a type of heart disease where the heart muscles become thicker than normal due to over contraction. This thickening makes it harder than normal due to over contraction. This thickening makes it harder for the heart to pump blood out to the rest of the body. In symptomatic oHCM people with the condition experience symptoms like shortness of breath, chest pain, fainting, high blood pressure and irregular heartbeats.
The study treatment aficamten, also called BAY3723113, is under development to treat symptomatic oHCM. It aims to reduce the activity of cardiac myosin, a protein that helps heart muscles to contract, and thereby preventing over contraction and muscle thickening.
Although treatment options are available for symptomatic oHCM, there is still need for other treatment options that help target the root cause of the condition. In this study, researchers want to understand about the effects and long-term safety of aficamten in Japanese people with symptomatic oHCM.
The main purpose of the study is to learn how well aficamten works in Japanese with symptomatic oCHM.
For this, the researchers will check how participant's heart blood flow changes after 6 months of treatment. They do this by measuring the pressure needed for blood to leave the heart using a test called the left ventricular outflow tract (LVOT) gradient and a special breathing technique called Valsava maneuver.
Researchers will also look for:
* the number of participants who will have at least 1 level improvement on a scale doctors use to assess the effect of heart problems on daily activities after 3 and 6 months of treatment
* the change in the impact of heart problems on participant's daily lives based on their feedback on a questionnaire called Kansas City Cardiomyopathy Questionnaire - Clinical Summary Score (KCCQ-CSS) after 3 and 6 months of treatment.
This study will have 2 treatment periods: main treatment period and long-term treatment period. During the main treatment period, participants will take aficamten tablets once daily by mouth for up to 6 months. After completing this period, the participants who can join the long-term treatment period will continue taking aficamten until the drug becomes commercially available in Japan or the study ends.
Each participant will be in the study as long as they benefit from the treatment.
Participants will visit the study site:
* once before the treatment starts
* 9 times with a gap of 2 to 4 weeks between the visits during treatment under the main treatment period, and in the long-term treatment period, participants will visit almost every 3 months until the treatment ends.
* then 2 more times with a gap of 1 month between the visits after the treatment ends.
During the study, the study doctors and their team will:
* check participant's health by performing tests such as blood and urine tests, and checking heart health using an electrocardiogram (ECG) and echocardiogram (ECHO)
* ask the participants questions about how they are feeling and what adverse events are they having
An adverse event is any medical problem that a participant has during a study. Study doctors keep track of all adverse events, irrespective if they think it is related or not to the study treatment. In addition, the participants will be asked to complete a questionnaire on quality of life at certain time points during the study.
If the participant benefits from the treatment, treatment with aficamten after the end of the study might be possible.

Start Date30 Jun 2025

Sponsor / Collaborator

Bayer AG

JPRN-jRCT2031250066

/ RecruitingPhase 3

A Phase 3, Multi-center, Randomized, Double-blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non-obstructive Hypertrophic Cardiomyopathy. (A study of aficamten in adults with symptomatic non-obstructive hypertrophic cardiomyopathy (ACACIA-HCM))

Start Date14 Apr 2025

Sponsor / Collaborator

Cytokinetics, Inc.

100 Clinical Results associated with Aficamten

100 Translational Medicine associated with Aficamten

100 Patents (Medical) associated with Aficamten

121

Literatures (Medical) associated with Aficamten

01 Jul 2026·AMERICAN JOURNAL OF CARDIOLOGY

Efficacy of Aficamten in Hypertrophic Cardiomyopathy Patients With Very-High Left Ventricular Outflow Tract Gradients

Article

Author: Veselka, Josef ; Coats, Caroline J ; Nassif, Michael E ; Abraham, Theodore P ; Claggett, Brian L ; Wohltman, Amy ; Gimeno, Ramon ; Miao, Zi Michael ; Malik, Fady I ; Barriales-Villa, Roberto ; Heitner, Stephen B ; Olivotto, Iacopo ; Maron, Martin S ; Masri, Ahmad ; Januzzi, James L ; Kupfer, Stuart ; Jacoby, Daniel L ; Hegde, Sheila M

This sub-analysis of SEQUOIA-HCM (NCT05186818) evaluated the efficacy and safety of aficamten in obstructive hypertrophic cardiomyopathy (oHCM) and very-high Valsalva left ventricular outflow tract gradients (LVOT-G). Patients with oHCM and Valsalva LVOT-G ≥100 mm Hg (n = 73) were randomized to aficamten (n = 33) or placebo (n = 40) for 24 weeks. The primary endpoint was proportional change in Valsalva LVOT-G from baseline to Week 24. Secondary endpoints included the proportion of patients achieving Valsalva LVOT-G < 30 mm Hg, absolute change in Valsalva LVOT-G, Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CCS), New York Heart Association (NYHA) functional class, NT-proBNP, and exercise capacity (peak oxygen uptake [pVO₂], workload), and time eligible for septal reduction therapy (SRT). Over 24 weeks, aficamten significantly reduced Valsalva LVOT-G by 66% from 123 ± 28 mm Hg to 41 ± 30 mm Hg (p = 0.001), including to <30 mm Hg in 42% of aficamten patients (p <0.001). Aficamten was also associated with symptom relief: 16 patients (48%) had ≥1 improvement in NYHA class, including 9 with both class I and ≥5-point increase in KCCQ-CSS. Compared with placebo, aficamten substantially decreased NT-proBNP concentration (‒85%; p = 0.001) and increased pVO₂ (+1.8 ml/kg/min; p = 0.003). Aficamten also reduced time eligible for SRT (p = 0.002) without any clinically relevant decrease in systolic function (ejection fraction <50%). Aficamten effectively reduced gradients in patients with oHCM and very-high Valsalva LVOT-G. Hemodynamic changes were associated with enhanced exercise capacity and symptom relief, underscoring aficamten treatment benefit across the spectrum of LVOT-G.

01 Jun 2026·DRUGS

Aficamten: First Approval

Review

Author: Shirley, Matt

Aficamten (MYQORZO™) is a small-molecule cardiac myosin inhibitor being developed by Cytokinetics for the treatment of hypertrophic cardiomyopathy (HCM). Supported by the findings of the phase III, randomised, double-blind, placebo-controlled SEQUOIA-HCM trial, in December 2025 aficamten was approved in both China and the USA to improve functional capacity and symptoms in adults with symptomatic obstructive HCM (oHCM). Subsequently, in February 2026, aficamten was also approved in the EU for the treatment of symptomatic oHCM in adult patients. Aficamten is also in phase III evaluation for use in the treatment of non-obstructive HCM (nHCM) in adults. This article summarises the milestones in the development of aficamten leading to this first approval for symptomatic oHCM.

01 Jun 2026·Indian Heart Journal

Medical management of hypertrophic cardiomyopathy

Review

Author: Goel, Vrinda ; Girish, M P ; Gupta, Mohit D

Hypertrophic cardiomyopathy (HCM) is a genetically determined myocardial disease in which symptoms are driven not simply by ventricular hypertrophy, but by a combination of dynamic left ventricular outflow tract obstruction (LVOTO), impaired diastolic filling and other factors.The therapy for HCM differs fundamentally from routine heart failure management and must be mechanism based. In obstructive HCM, the pharmacologic objective is to blunt hypercontractility, lengthen diastole, preserve loading conditions, and reduce the LVOT gradient. In non-obstructive HCM, management is focused on symptom control, heart-rate moderation, careful volume management, and treatment of arrhythmias and congestion. Non-vasodilating beta-blockers, non-dihydropyridine calcium-channel blockers, and disopyramide have constituted the foundation of medical therapy. The contemporary era has added sarcomere-directed treatment with cardiac myosin inhibitors, particularly mavacamten and aficamten, The present review provides a pragmatic algorithm for publication-level clinical use in contemporary practice.

330

News (Medical) associated with Aficamten

31 Jul 2026

·firstwordpharma.com

Three's an IPO crowd: biotech trio set to raise $575M in total

Gearing up for their public debuts, a trio of biotechs have set terms for their respective offerings this week, which collectively could raise close to $600 million. Lining up to make a run at the IPO window are cardiology company Braveheart Bio, inflammatory disease–focused Attovia and Vogenx, which is advancing an SGLT1 inhibitor for gastric and metabolic conditions. The three companies are part of a cohort of seven total biotechs that joined the IPO queue in the third quarter, after a gangbusters first half. They trail behind Apnimed, which set terms for a $150-million IPO earlier this week, and Scribe Therapeutics, the first biotech to make its debut in the second half with a $128.7-million raise. Still waiting in the wings are Latigo Biotherapeutics and BlossomHill Therapeutics.For related IPO analysis, see Spotlight On: Investors regain appetite for biotech IPOs.Braveheart's cardiac myosin betThe largest raise of the latest bunch could go to Braveheart, which proposed to sell 18.8 million shares at a range of $15 to $17 each. At the midpoint, the firm would raise $300 million and be valued at more than $1.1 billion. With its IPO cash, the biotech plans to launch a pair of Phase III trials evaluating its sole programme, BHB-1893, in both obstructive and non-obstructive hypertrophic cardiomyopathy (HCM). Braveheart in-licensed ex-China rights to the oral cardiac myosin inhibitor in a deal last year with Jiangsu Hengrui Pharmaceuticals worth up to $1.1 billion.If successful in obstructive HCM, BHB-1893 will compete with rival cardiac myosin inhibitors Camzyos (mavacamten) from Bristol Myers Squibb and Cytokinetics' Myqorzo (aficamten).Attovia's ATTOBODIESAttovia is targeting the next-largest offering, having proposed to sell 12.5 million shares at $15 to $17 each. The company would raise $200 at the midpoint and garner a valuation of more than $600 million. The biotech is developing a trio of programmes called ATTOBODIES — biparatopic biologics that use spatial positioning technology to attain picomolar binding affinity. The IPO proceeds will help Attovia next year launch a Phase II trial evaluating lead candidate ATTO-1310 — an ATTOBODY-based IL-31–inhibiting Fc-fusion protein — for chronic pruritus and high-itch atopic dermatitis (AD).The company also has two preclinical programmes. ATTO-2306 is an ATTOBODY-based IL-13/IL-31–targeting bispecific for AD. while ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein designed to block TL1A, IL-23 and integrin a4ß7, could help treat inflammatory bowel disease.Vogenx's SGLT1 inhibitorThe third company looking to go public is Vogenx, which is aiming to sell 6.3 million shares at a range of $11 and $13. At the midpoint, it would raise $75 million and secure a valuation of more than $165 million. The offering will help fund the Phase IIb EMERGE study of its lead candidate mizagliflozin, an oral small-molecule inhibitor of SGLT1, a transporter in the gastrointestinal tract that moves dietary glucose into the bloodstream. Vogenx is developing mizagliflozin for post-bariatric hypoglycaemia (PBH), a side effect of bariatric weight-loss surgeries that causes low blood sugar after eating and can lead to confusion, anxiety, shaking and even fainting. It is also studying the asset for gastroparesis and GIP-dependent Cushing’s syndrome (GDCS).

Phase 2IPOPhase 1

30 Jul 2026

·www.biospace.com

Cytokinetics Announces MHRA Marketing Authorisation for MYQORZO®▼ (aficamten) and Positive Guidance from NICE for Symptomatic Obstructive Hypertrophic Cardiomyopathy in England and Wales

Authorisation from MRHA and Recommendation from NICE This announcement is intended for business and financial media and investors only SOUTH SAN FRANCISCO, Calif., July 30, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the Medicines and Healthcare products Regulatory Agency (MHRA) has granted MYQORZO® ( aficamten ) a marketing authorisation across the United Kingdom for the treatment of symptomatic (New York Heart Association, NYHA class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in eligible adult patients. At the same time the National Institute for Health and Care Excellence (NICE) has issued guidance recommending aficamten for use in eligible adult patients in England and Wales. The guidance from NICE states that aficamten can be used as an option to treat symptomatic oHCM in eligible adults with a NYHA class of II to III. It can only be used as an add-on to individually optimised standard care including beta-blockers, non-dihydropyridine calcium-channel blockers or disopyramide, or alone if these treatments are contraindicated, and if the company provides it according to the commercial arrangement. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); “We are pleased to have secured a marketing authorisation for aficamten and to see positive guidance from NICE for eligible adult patients in England and Wales,” said Joseph Dagher, Senior Vice President and Head of Europe, Cytokinetics. “We are grateful for the collaborations that made this review possible for concurrent MHRA and NICE decisions and are committed to supporting access for eligible adult patients through the NHS upon availability expected later this year.” The MHRA assessment of aficamten drew on data from SEQUOIA-HCM, a phase 3 multicentre double-blind placebo-controlled randomised study in 282 adults (142 aficamten , 140 placebo) treated for 24 weeks. 1 The primary endpoint was the change from baseline to Week 24 in peak oxygen uptake (pVO 2 ) measured by cardiopulmonary exercise testing. Aficamten resulted in a statistically significant improvement in peak oxygen uptake compared with placebo (mean change 1.8 mL/kg/min with aficamten versus 0.0 mL/kg/min with placebo; least squares mean difference 1.7 mL/kg/min, 95% confidence interval 1.0 to 2.4; p < 0.001). 1 Further information, including efficacy and safety data, is provided in the aficamten Summary of Product Characteristics. 2 The most commonly reported adverse reactions with aficamten were hypertension (7.7%), palpitations (7.0%), dizziness (4.2%) and systolic dysfunction (3.5%). 2 ▼ MYQORZO ( aficamten ) is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at yellowcard.mhra.gov.uk or by searching for MHRA Yellow Card in the Google Play or Apple App Store. About Aficamten Aficamten is a cardiac myosin inhibitor authorised in the United Kingdom for the treatment of symptomatic (NYHA class II-III) oHCM in eligible adult patients. In patients with oHCM, myosin inhibition with aficamten reduces cardiac contractility and, consequently, left ventricular outflow tract (LVOT) obstruction. Aficamten has a predictable exposure-response relationship and a reversible mechanism of action. 1 About Obstructive Hypertrophic Cardiomyopathy Hypertrophic cardiomyopathy (HCM) is a disease in which the heart muscle becomes abnormally thick. In oHCM, thickened heart muscle blocks blood flow, and the inside of the left ventricle becomes smaller, stiffer and less able to relax and fill with blood. This limits the heart's pumping function, leading to reduced exercise capacity and a variety of symptoms. HCM is the most common monogenic inherited cardiovascular disorder, affecting approximately 1 out of 500 Europeans, according to European Society of Cardiology guidelines. 3 Approximately half of patients with HCM have oHCM. 4 People with oHCM are at high risk of also developing cardiovascular complications including atrial fibrillation, stroke and mitral valve disease. 5 People with oHCM are at risk of potentially fatal ventricular arrhythmias, which is one of the leading causes of sudden cardiac death in younger people or athletes. 6 A subset of patients with oHCM are at high risk of progressive disease leading to dilated cardiomyopathy and heart failure necessitating cardiac transplantation. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology and advancing a pipeline of potential new medicines. For additional information about Cytokinetics, visit and follow us on X , LinkedIn , Facebook and YouTube . Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to the enrollment, expected results or timing of completion of any of our clinical trials, the clinical meaningfulness, persuasiveness or interpretation of clinical trial results, including for purposes of regulatory approval, labeling, or market acceptance, the results of long-term, secondary or exploratory analyses, including analyses of time to first cardiovascular event, statements relating to our ability to obtain regulatory approval for aficamten in nonobstructive hypertrophic cardiomyopathy in any particular date, if ever, the number of patients comprising the eligible treatment population for aficamten , or market acceptance of aficamten for the treatment of nonobstructive hypertrophic cardiomyopathy. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to, potential difficulties or delays in the development, testing, regulatory approvals for trial commencement, progression or product sale or manufacturing of Cytokinetics' drug candidates that could slow or prevent clinical development or product approval; Cytokinetics' drug candidates may have adverse side effects or inadequate therapeutic efficacy; the FDA or foreign regulatory agencies may delay or limit Cytokinetics' ability to conduct clinical trials; Cytokinetics may be unable to obtain or maintain patent or trade secret protection for its intellectual property; standards of care may change, rendering Cytokinetics' drug candidates obsolete; and competitive products or alternative therapies may be developed by others for the treatment of indications Cytokinetics' drug candidates and potential drug candidates may target. For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission including the risk factors included in Cytokinetics' most recent Annual Report on Form 10-K and subsequent reports filed with the SEC. CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. MYQORZO® is a registered trademark of Cytokinetics in the U.S., the European Union and the United Kingdom. References Maron MS, et al. Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy. N Engl J Med. doi:10.1056/NEJMoa2401424 MYQORZO ( aficamten ) UK Summary of Product Characteristics. Available from Cytokinetics upon request ESC Clinical Practice Guidelines. ESC European Society of Cardiology. Accessed July 23, 2025. Butzner M, et al. Epidemiology of Hypertrophic Cardiomyopathy in the United States From 2016 to 2023. JACC Adv. 2026;5(2):102552. doi:10.1016/j.jacadv.2025.102552 Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, et al. 2011 ACCF/AHA guidelines for the diagnosis and treatment of hypertrophic cardiomyopathy. A report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Journal of the American College of Cardiology and Circulation, 58, e212-260. Hong Y, Su WW, Li X. Risk factors of sudden cardiac death in hypertrophic cardiomyopathy. Current Opinion in Cardiology. 2022 Jan 1;37(1):15-21. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757

24 Jul 2026

·www.biospace.com

Cytokinetics to Announce Second Quarter Results on August 6, 2026

SOUTH SAN FRANCISCO, Calif., July 23, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report second quarter results on August 6, 2026 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics’ senior management will host a conference call at 4:30 PM Eastern Time to discuss financial results and provide business updates. The conference call will be simultaneously webcast and can be accessed from the Investors & Media section of Cytokinetics’ website at or directly at the following link: Cytokinetics Q2 2026 Earnings Conference Call . An archived replay of the webcast will be available via Cytokinetics’ website for six months. About Cytokinetics Cytokinetics is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction. Cytokinetics’ MYQORZO ® ( aficamten ) is a cardiac myosin inhibitor approved in the U.S., Europe and China for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM). Following positive topline results in ACACIA-HCM, a Phase 3 clinical trial of aficamten in patients with non-obstructive HCM (nHCM), the company plans to discuss the results with the U.S. FDA and other regulatory authorities. Cytokinetics is also developing omecamtiv mecarbil , an investigational cardiac myosin activator for the potential treatment of patients with heart failure with severely reduced ejection fraction and ulacamten , an investigational cardiac myosin inhibitor for the potential treatment of heart failure with preserved ejection fraction, while continuing pre-clinical research and development in muscle biology. ezstandalone.cmd.push(function () { ezstandalone.showAds(131); }); For additional information about Cytokinetics, visit and follow us on X , LinkedIn , Facebook and YouTube . Disclaimer Omecamtiv mecarbil and ulacamten are investigational medicines. They have not been approved nor determined to be safe or efficacious for any disease state or any indication by FDA or any other regulatory agency. Forward-Looking Statements This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the “Act”). Cytokinetics disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act’s Safe Harbor for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to Cytokinetics’ and its partners’ research and development activities of Cytokinetics’ product candidates. Such statements are based on management’s current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to Cytokinetics’ business outlines in Cytokinetics’ filings with the Securities and Exchange Commission. Forward-looking statements are not guarantees of future performance, and Cytokinetics’ actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that Cytokinetics makes in this press release speak only as of the date of this press release. Cytokinetics assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release. CYTOKINETICS® and the CYTOKINETICS C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries. MYQORZO ® is a registered trademark of Cytokinetics in the U.S. and the European Union. Contact: Cytokinetics Diane Weiser Senior Vice President, Corporate Affairs (415) 290-7757

100 Deals associated with Aficamten

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Hypertrophic obstructive cardiomyopathy	China	Cytokinetics, Inc.	16 Dec 2025

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	United States	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	China	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Japan	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Argentina	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Australia	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Brazil	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Canada	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Denmark	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	France	Cytokinetics, Inc.	31 Aug 2023
Hypertrophic Cardiomyopathy without Obstruction	Phase 3	Germany	Cytokinetics, Inc.	31 Aug 2023

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05767346 (MAPLE-HCM, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	aficamten (Aficamten)	tivjrkwcnp(szggyngcpc) = lwjbsbwvor moaenvhgvx (vhgbrxjwsa, 2.767) View more	-	09 Jun 2026
				Metoprolol (Metoprolol)	tivjrkwcnp(szggyngcpc) = bsqzidkvpo moaenvhgvx (vhgbrxjwsa, 2.186) View more
NCT05186818 (SEQUOIA-HCM, CTgov)	Phase 3	Hypertrophic obstructive cardiomyopathy	282	Aficamten (Aficamten up to 20 mg)	zqkbcighxi(qftugfwxms) = nwqaqsbeoj dnayziqccz (xcygcoksir, 0.25) View more	-	03 Mar 2026
				Placebo to match aficamten (Placebo to Match Aficamten)	zqkbcighxi(qftugfwxms) = dllrnqptch dnayziqccz (xcygcoksir, 0.25) View more
NCT04219826 (REDWOOD-HCM Cohort 4 \| REDWOOD-HCM, CTgov)	Phase 2	Cardiomyopathy, Hypertrophic	96	CK-3773274 (Cohort 1 (oHCM) - Aficamten)	txnuixmxeo = xzgzjprqqj cqpauckogi (sanegixzxp, fwhgqedlgf - qitdppxxmw) View more	-	24 Feb 2026
				CK-3773274 (Cohort 2 (oHCM) - Aficamten)	txnuixmxeo = cibpeapxtv cqpauckogi (sanegixzxp, lvspszabty - enfxmxugdd) View more
NCT06412666 \| NCT05186818 (CEDAR-HCM, Pubmed \| Circ Heart Fail)	Phase 3	Hypertrophic obstructive cardiomyopathy	65	Aficamten	cdooxblvtl(ftboarcrsp) = cxzuguisnp ubeyehvbze (eltuuloohu )	Positive	05 Dec 2025
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten 5 to 20 mg	skxisrvcsx(znnrudjbuq) = pnutmdylhe vtvyfanojd (mrrsnackmc ) View more	Positive	01 Dec 2025
				Metoprolol 50 to 200 mg	-
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	wurdflwiax(dwjxxpchsz) = sovqgtkkza vhcrnsqrul (tszdwqooxp ) View more	Positive	01 Nov 2025
				Metoprolol	wurdflwiax(dwjxxpchsz) = uvikeawhsm vhcrnsqrul (tszdwqooxp ) View more
NCT05767346 (MAPLE-HCM, Pubmed \| J Am Coll Cardiol)	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	sxcpkdkngp(udfuvloskb): Difference = 7.8 (95.0% CI, 3.3 - 12.3), P-Value = < 0.001 View more	Positive	01 Nov 2025
				Metoprolol
NCT05767346 (MAPLE-HCM, Company_Website) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	-	Aficamten	vgdceqqudl(ykskemgrid) = oszkbqvfen ovpfnmyhtn (ikulvpbhxa ) View more	Superior	29 Sep 2025
				Metoprolol	-
NCT04848506 (FOREST-HCM, Company_Website) Manual	Phase 2/3	Hypertrophic Cardiomyopathy without Obstruction	34	Aficamten (post-REDWOOD-HCM Cohort 4)	tkgnpkdhqn(lsglmpgota) = zahsoyeqht iyreffhopo (gkjouxzcji ) View more	Positive	29 Sep 2025
NCT05767346 (MAPLE-HCM, Pubmed \| N Engl J Med) Manual	Phase 3	Hypertrophic obstructive cardiomyopathy	175	Aficamten	lpdutmsxtm(nxjkizpica) = niiwdqlior dikhjzrjvr (avsskusodk, 0.5 - 1.7)	Superior	11 Sep 2025
				Metoprolol	lpdutmsxtm(nxjkizpica) = aiqbokwghe dikhjzrjvr (avsskusodk, -1.7 to -0.8)

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis